PE(14:0/22:4(7Z,10Z,13Z,16Z))

Metabolite details

Identifier

KUPNWZACJRZMJD-SIOSMUJOSA-N

InChI Key

KUPNWZACJRZMJD-SIOSMUJOSA-N

IUPAC name

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoate

Preferred name

PE(14:0/22:4(7Z,10Z,13Z,16Z))

INN name

—

Synonym

—

ChEBI

CHEBI:170375

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2.
• Transcriptional differentiation of Trypanosoma brucei during in vitro acquisition of resistance to acoziborole
• Metabolic characterization of the natural progression of chronic hepatitis B (Lipid assays).
• Changes and correlations of intestinal flora and liver metabolite profiles in mice with gallstones
• Mechanical force promotes dimethylarginine dimethylaminohydrolase 1-mediated hydrolysis of the metabolite asymmetric dimethylarginine to enhance bone formation
• Lipidomic Changes in the Liver of Beagle Dogs Associated with Toxocara canis Infection
• Effects of Radiofrequency Field from 5G Communications on fecal microbiome and metabolome profiles in mice
• LION-web validation lipidomics experiments (FA-incorporation, membrane fluidty)

Observed in differential profiles

• non_COVID_19_healthy_vs_non_critical_COVID_19
• WT_vs_WT_Aco
• Control_vs_Immune_Tolerant
• Control_vs_Immune_Tolerant
• Control_vs_Immune_Tolerant
• Control_vs_Lithogenic_Diet
• Control_vs_Exercise
• Control_12h_vs_Toxocara canis_12h
• Sham_vs_Radiofrequency
• BSA_Control_vs_AA